8-K/A: Pelthos Therapeutics Reports Deepening Losses Amid ZELSUVMI Launch

Pelthos Therapeutics Inc. (formerly Channel Therapeutics) reported significantly increased net losses and operating expenses for LNHC, Inc. following its merger, despite the recent FDA approval and commercial launch of ZELSUVMI.

Summary

• Pelthos Therapeutics Inc. (formerly Channel Therapeutics Corporation) completed a merger with LNHC, Inc. (a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated) on July 1, 2025.
• The company's name changed to Pelthos Therapeutics Inc. and its common stock commenced trading on the NYSE American under the symbol PTHS on July 2, 2025.
• LNHC, Inc. reported a net loss of $16.961 million for the three months ended June 30, 2025, a significant increase from $5.740 million for the same period in 2024.
• For the six months ended June 30, 2025, LNHC's net loss was $24.472 million, up from $13.242 million in 2024.
• Revenue for LNHC increased to $317 thousand for the three months ended June 30, 2025 (up 45%) and $611 thousand for the six months ended June 30, 2025 (up 40%), primarily from deferred revenue recognition from the Sato Agreement.
• Operating expenses for LNHC surged, with selling, general and administrative expenses reaching $12.384 million for the three months ended June 30, 2025 (up 290%) and $16.646 million for the six months ended June 30, 2025 (up 135%).
• A $5.0 million milestone payment to Ligand related to ZELSUVMI commercialization activities contributed significantly to the increase in SG&A expenses.
• Research and development expenses for LNHC increased to $3.938 million for the three months ended June 30, 2025 (up 72%) and $6.670 million for the six months ended June 30, 2025 (up 19%).
• The company completed a PIPE Financing, raising approximately $50.1 million in gross proceeds, consisting of $50.0 million in cash and $0.1 million from convertible note conversion.
• ZELSUVMI (berdazimer gel, 10.3%), the company's lead product for molluscum contagiosum, received FDA approval on January 5, 2024, and is the first FDA-approved topical nitric oxide releasing agent for at-home use.
• The company faces substantial doubt about its ability to continue as a going concern, dependent on raising additional capital and generating sufficient revenue.
• A one-for-ten reverse stock split of common stock was effected on July 1, 2025.
• Ligand Pharmaceuticals Incorporated holds 49.0% beneficial ownership, and 3i LP holds 9.8% of the common stock.
• The company has 93 full-time employees as of September 15, 2025, and is building its sales, marketing, and commercial team for ZELSUVMI.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significantly increased net losses, a 'going concern' warning, and substantial increases in operating expenses, which overshadow the positive FDA approval and recent capital raise. The company's financial stability remains highly uncertain.

Positives

• ZELSUVMI (berdazimer gel, 10.3%) received FDA approval on January 5, 2024, as the first and only topical prescription medication for molluscum contagiosum that can be administered at home.
• The company estimates a significant market opportunity for molluscum contagiosum, affecting approximately 17 million people in the U.S. with an annual incidence of 3-6 million.
• A PIPE Financing raised approximately $50.1 million in gross proceeds, providing capital for commercialization efforts.
• The company possesses an exclusive license to the NITRICIL Technology Platform from Ligand, with 14 issued U.S. patents covering ZELSUVMI, potentially extending to 2037.
• Internal manufacturing capacity for the active pharmaceutical ingredient (API) berdazimer sodium is sufficient for current sales forecasts and has excess capacity for future demand without significant capital expenditures.
• Revenue from the Sato Agreement increased by 45% and 40% for the three and six months ended June 30, 2025, respectively, indicating progress in existing collaborations.

Negatives

• LNHC, Inc. reported significantly increased net losses, reaching $16.961 million for Q2 2025 and $24.472 million for H1 2025, indicating a worsening financial performance.
• Operating expenses, particularly selling, general and administrative expenses, surged by 290% in Q2 2025, driven by a $5.0 million milestone payment to Ligand and commercialization costs.
• The company's financial statements contain a 'going concern' qualification, raising substantial doubt about its ability to continue operations beyond one year without additional capital.
• Despite the PIPE financing, the company expects to incur significant expenses and operating losses for the foreseeable future, requiring additional funding.
• The company has a limited operating history and commercialization experience, making future success and viability difficult to evaluate.
• Interest expense increased by 145% in Q2 2025, primarily due to a long-term liability to Reedy Creek and an increased effective interest rate based on ZELSUVMI sales forecasts.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses and dependence on raising capital.
• Incurrence of significant losses until ZELSUVMI revenue is sufficient to fund operations, with no assurance of achieving or maintaining profitability.
• Commercialization efforts for ZELSUVMI may not be successful, or may not generate expected revenue or profit levels.
• ZELSUVMI may fail to achieve market acceptance by physicians, patients, and third-party payors due to competition, efficacy, safety, convenience, or pricing.
• Inability to establish effective sales, marketing, and distribution capabilities for ZELSUVMI or future product candidates.
• Potential for undesirable side effects or other properties of ZELSUVMI or product candidates to limit commercial profile, expose to product liability claims, or delay/prevent regulatory approval.
• Intense competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as alternative treatments and off-label drug uses.
• Delays or disruptions in the supply chain and manufacturing of products could adversely affect sales, development timelines, and increase costs.
• Limited experience in producing commercial scale products utilizing the NITRICIL technology, with risks in manufacturing processes and analytical methods.
• Reliance on third parties for raw materials, logistics, and fill/finish manufacturing, posing risks of delays, disruptions, and quality control issues.
• Business involves hazardous materials, requiring compliance with environmental laws and regulations, which can be expensive and restrict operations.
• Adverse effects from inflation or trade tariffs on liquidity, business, financial condition, and results of operations.
• Dependence on third parties to conduct preclinical studies and clinical trials, with risks if they do not perform contractual duties or meet deadlines.
• Misconduct or improper activities by employees, contractors, or partners could expose the company to liability and harm its reputation.
• Reliance on in-licenses from third parties (e.g., Ligand, UNC); loss of these rights would materially and adversely affect the business.
• Third-party intellectual property may prevent development, or owned IP may not prevent competition, leading to expensive and time-consuming legal issues.
• Inability to obtain and maintain sufficient intellectual property protection, or if the scope is not broad enough, competitors could develop similar technologies.
• Issued patents directed to the NITRICIL platform and technology could be found invalid or unenforceable if challenged.
• Changes in patent law could diminish the value of patents, impairing the ability to protect products.
• Claims challenging the inventorship of patents and other intellectual property could lead to litigation and loss of rights.
• Inability to protect the confidentiality of information and trade secrets, materially affecting technology value and competitive position.
• Inadequate protection of trademarks and trade names could harm brand recognition.
• Current and future healthcare reform legislation or regulation may increase commercialization difficulty and costs, and adversely affect pricing.
• Failure to comply with reporting and payment obligations under government pricing programs (Medicaid Drug Rebate Program, 340B, VA FSS) could result in penalties and fines.
• Subject to federal, state, and foreign healthcare fraud and abuse laws; non-compliance could lead to criminal sanctions, damages, and reputational harm.
• Changes in and actual or perceived failures to comply with data privacy, security, and protection laws could adversely affect business and financial performance.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Risks related to handling of hazardous materials and compliance with environmental safety regulations.
• Potential adverse effects from federal government deficit reduction policies on the biopharmaceutical industry.
• Control or significant influence over matters submitted to stockholders by executive officers, directors, and principal stockholder (Ligand).
• Impairment charges pertaining to goodwill, identifiable intangible assets, or other long-lived assets from mergers and acquisitions could adversely impact results.
• Market fluctuations and economic downturns could negatively affect results of operations and liquidity needs.
• Risks arising from pandemic and epidemic diseases, potentially disrupting business activities and supply chains.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future until revenue from ZELSUVMI is sufficient to fund operations. It anticipates needing to raise additional capital to support commercialization activities and other operational costs, with no assurance of securing such funds on acceptable terms.

Management Comments

• Management believes that ZELSUVMI is likely to complement or represent a differing treatment regimen of current procedural treatments administered in medical settings.
• Management estimates that molluscum contagiosum infections afflict approximately 17 million people of all ages in the United States.
• Management believes that pediatricians will be key to expanding the market, increasing peak sales, and sales and marketing efficiency for ZELSUVMI.
• Management believes the current API theoretical manufacturing capacity could be roughly doubled, if needed, due to higher than expected sales demand or partnerships, without needing material capital expenditures.
• Management believes there is substantial doubt about the company's ability to continue to operate as a going concern and to fund its operations through at least the next twelve months.

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. ZELSUVMI's approval as the first FDA-approved at-home topical treatment for molluscum contagiosum positions it uniquely against existing procedural treatments (cryosurgery, cantharidin, curettage) and off-label drug uses. The market for molluscum contagiosum is currently undertreated, suggesting a significant opportunity for ZELSUVMI to expand the treated patient population, particularly among pediatricians. However, the industry faces increasing scrutiny over drug pricing and reimbursement, with legislative changes like the Inflation Reduction Act potentially impacting future revenues and profitability.

Comparison to Industry Standards

• ZELSUVMI is positioned as the first and only FDA-approved prescription topical medication for at-home treatment of molluscum contagiosum, differentiating it from existing in-office procedural treatments like cryosurgery and cantharidin application.
• The company's NITRICIL technology platform, validated by ZELSUVMI's FDA approval, demonstrates a novel approach to nitric oxide delivery, potentially offering a differentiated product candidate pipeline compared to traditional small molecule or biologic development.
• The reported net losses and 'going concern' qualification for LNHC, Inc. (and by extension, Pelthos Therapeutics) are indicative of the high-risk, capital-intensive nature of early-stage biopharmaceutical commercialization, where significant R&D and SG&A investments precede substantial revenue generation. This is common for companies launching their first commercial product.
• The company's reliance on a centralized cash management and financing program from Ligand prior to the merger, and subsequent dependence on capital raises, aligns with typical funding models for smaller biopharmaceutical entities that lack established revenue streams.

Management Changes

Corporate Governance

Related Party Transactions

• Ligand Pharmaceuticals Incorporated (Parent Company): Issued approximately 31,278 shares of Series A Preferred Stock in the Merger. Ligand participated in the PIPE Financing, investing $18.0 million. Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI and $10 million in commercialization and sales-based milestones, with a $5 million milestone incurred in Q2 2025. Ligand also has a Master Services Agreement for API supply and technology transfer. The Ligand Bridge Note (max $18.0 million) was repaid at the Merger closing.
• Nomis RoyaltyVest LLC (NRV): Sold a portion of ZELSUVMI revenue payments. NRV receives a 1.5% royalty on net sales (ex-Japan) and 3.46% of non-royalty sublicensing payments prior to the Initial Royalty Term expiration.
• NRV, Ligand, and Madison Royalty LLC: Sold a portion of revenue payments for 'Channel Covered Products.' NRV receives a 5.3% royalty, Ligand 1.7%, and Madison 1.5% on Net Sales (pre-initial royalty term expiration).
• University of North Carolina at Chapel Hill (UNC): The UNC License Agreement, which grants exclusive rights to NITRICIL compounds, was assigned to Ligand, but LNHC remains subject to obligations related to milestone and royalty payments.
• Sato Pharmaceutical Co., Ltd. (Sato): The Sato Agreement, granting exclusive rights for SB204 and SB206 in Japan, was assigned to Ligand, but LNHC assumed contractual liabilities, and Ligand is obligated to pass through future payments to LNHC.
• Reedy Creek Investments LLC: Received $25.0 million in funding for development of SB206, SB204, and SB414, with an obligation to pay a low single-digit royalty on net sales in the US, Mexico, or Canada.
• Benuvia Operations LLC: Entered into an exclusive licensing agreement for Diclofenac Spray Formulation, Rizatriptan, and Ondansetron sublingual spray formulations. The company will pay a 6.5% royalty on net sales for up to 15 years. Todd Davis, a director, serves as CEO of Benuvia Holdings, LLC, the ultimate parent company of Benuvia.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future capital raises and potential value erosion due to recurring losses and 'going concern' doubt. The one-for-ten reverse stock split may impact per-share metrics. Ligand, as a major shareholder, has significant influence.
• Employees: The company has recently completed hiring a sales, marketing, and commercialization team for ZELSUVMI, indicating job creation and growth opportunities, but the 'going concern' status could create uncertainty.
• Customers (Patients/Healthcare Providers): ZELSUVMI's FDA approval and at-home administration offer a new, convenient treatment option for molluscum contagiosum, potentially improving patient access and outcomes. Co-pay assistance programs are planned to ease financial burden.
• Suppliers/Creditors: The 'going concern' qualification and reliance on future capital raises may increase perceived risk for suppliers and creditors. The repayment of the Ligand Bridge Note and the Reedy Creek liability are significant financial obligations.
• Regulatory Authorities: The company is subject to extensive regulation, and compliance with FDA, SEC, and other healthcare laws is critical for continued operations and product commercialization.

Next Steps

• Continue building the sales, marketing, and commercial team for ZELSUVMI's launch.
• Effectively commercialize ZELSUVMI to achieve broad physician and patient adoption.
• Generate sufficient revenue from ZELSUVMI sales to fund operations and achieve profitability.
• Raise additional capital to support ongoing operations and commercialization activities.
• Negotiate a development and funding agreement for the SB207 product program within one year of the Effective Date.
• File a resale registration statement with the SEC covering shares of Common Stock issuable upon conversion of Series A Preferred Stock.
• Comply with all applicable regulatory post-approval requirements for ZELSUVMI.

Key Dates

Recommendation

The filing reveals a company in a precarious financial position, marked by substantial and increasing net losses, a 'going concern' qualification, and a heavy reliance on future capital raises. While the FDA approval of ZELSUVMI is a positive, the significant surge in operating expenses, particularly SG&A, indicates high costs associated with commercialization that are currently far outstripping revenue. The multiple extensions of commercialization milestones for licensed products also suggest operational challenges. Given the high financial risk, the uncertainty of achieving profitability, and the need for further funding, a seasoned investor would likely recommend selling or avoiding this stock until there is clear evidence of sustainable revenue growth and a path to profitability.

Keywords

Pelthos Therapeutics, LNHC Inc, Merger, ZELSUVMI, Molluscum Contagiosum, Biopharmaceutical, FDA Approval, NITRICIL Technology, PIPE Financing, SEC Filing, Going Concern, Drug Commercialization, Pharmaceutical Industry, Topical Treatment, Patent Rights, Financial Losses, Operating Expenses, Capital Raise, Corporate Governance, Risk Factors